Last Min Clinical Hematology and oncology Passmedicine (part B)

Patients with Sjogren's syndrome have an increased risk of lymphoid malignancies
Philadelphia translocation, t(9;22) - good prognosis in CML, poor prognosis in AML + ALL
Polycythaemia rubra vera - JAK2 mutation
Polycythaemia rubra vera - around 5-15% progress to myelofibrosis or AML
Polycythaemia rubra vera is associated with a low ESR
Rasburicase - a recombinant version of urate oxidase, an enzyme that metabolizes uric acid
to allantoin
Screening for haemochromatosis
 general population: transferrin saturation > ferritin
 family members: HFE genetic testing
TTP - plasma exchange is first-line
Taxanes (e.g. Docetaxel) prevent microtubule disassembly
Tear-drop poikilocytes = myelofibrosis
Trastuzumab (Herceptin) - cardiac toxicity is common
Trimethoprim may cause pantcytopaenia
Venous thromoboembolism - length of warfarin treatment
 provoked (e.g. recent surgery): 3 months
 unprovoked: 6 months
Vincristine - peripheral neuropathy
Blood film abnormalities
Tear-drop poikilocytes - myelofibrosis
Drug adverse effects
Primaquine may cause haemolysis in patients with G6PD deficiency
Drug mechanism of action
Imatinib - inhibitor of the tyrosine kinase associated with the BCR-ABL
defect
Haemolytic anaemia
Extravascular haemolysis - warm autoimmune haemolytic anaemia

Comments

Popular posts from this blog

KEY points passmedicine for part-1 and part-2 (part-c)

KEY points pass medicine for part -1 and part-2 (part-b)